Severe Drug-Induced Liver Injury from Combination EncorafenibBinimetinib

Abstract EN

Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma.

Though generally tolerated well, mild to moderate aminotransferase elevations are common.

However, significant liver injury has not been demonstrated in the literature.

Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup.

He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range.